3514-15-6

Upstream product

• 61939-18-2 N-methyl-2-(1-methylindole)carboxamide 
• 27421-51-8 1-methyl-1H-indole-2-carboxaldehyde 
• 7732-18-5 water 
• 18450-24-3 ethyl N-methylindole-2-carboxylate 
• 3770-50-1 2-carbethoxyindole 
• 74-89-5 methylamine 
• 118618-61-4 1-methyl-1H-indole-2-carbonyl chloride 

Downstream Products

• 335059-15-9 2-bromo-N-methyl-N-[(1-methyl-1H-indol-2-yl)-methyl]-benzamide 
• 335059-11-5 2-[3-(acetylamino)-phenoxy]-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-benzamide 
• 335059-10-4 4-Amino-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-2-phenoxybenzamide 
• 335058-93-0 2-[2-(4-methoxyphenyl)-ethyl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)-methyl]-nicotinamide 
• 334999-87-0 {3-[(phenylamino)methyl]phenyl-4-nitro}-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide 
• 1428799-38-5 C₂₈H₂₈N₆O₂ 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial Fab I and can be used for the treatment of Staphylococcal infections.

FAB I INHIBITORS

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

Fab I inhibitors

Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infecti

Fab I inhibitors

Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment of bacterial infections.

Methods of agonizing and antagonizing FabK

The invention provides methods for using agonists and antagonists of FabK polypeptides, particularly to modulate the metabolism of bacteria or to treat bacterial infection.

Fab I inhibitors

Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment bacterial infections: wherein: R1is H, C1-6alkyl or Ar—C0-6alkyl; R2is H, C1-6alkyl, Ar—C0-6alkyl, HO—(CH2)n— or R′OC(O)—(CH2)n—; R3is A—C0-4alkyl, A—C2-4alkenyl, A—C2-4alkynyl, A—C3-4oxoalkenyl, A—C3-4oxoalkynyl, A—C1-4aminoalkyl, A—C3-4aminoalkenyl, A—C3-4aminoalkynyl, optionally substituted by any accessible combination of one or more of R10or R7; R5is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl; A is H, C3-6cycloalkyl, Het or Ar; R7is —COR8, —COCR′2R9, —C(S)R8, —S(O)kOR′, —S(O)kNR′R″, —PO(OR′), —PO(OR′)2, —B(OR′)2, —NO2, or tetrazolyl; R8is —OR′, —NR′R″, —NR′SO2R′, —NR′OR′, or —OCR′2CO(O)R′; R9is —OR′, —CN, —S(O)rR′, —S(O)kNR′2, —C(O)R′, C(O)NR′2, or —CO2R′; R10is H, halo, —OR11, —CN, —NR′R11, —NO2, —CF3, CF3S(O)r—, —CO2R′, —CONR′2, A—C0-6alkyl-, A—C1-6oxoalkyl-, A—C2-6alkenyl-, A—C2-6alkynyl-, A—C0-6alkyloxy-, A—C0-6alkylamino- or A—C0-6alkyl —S(O)r—; R11is R′, —C(O)R′, —C(O)NR′2, —C(O)OR′, —S(O)kR′, or —S(O)kNR′2; R′ is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl; R″ is R′, —C(O)R′ or —C(O)OR′; R′″ is H, C1-6alkyl, Ar—C0-6alkyl, HO-(CH2)2—, R′C(O)—, (R′)2NC(O)CH2— or R′S(O)2—; X is H, C1-4alkyl, OR′, SR′, C1-4alkylsulfonyl, C1-4alkylsulfoxyl, —CN, N(R′)2, CH2N(R′)2, —NO2, —CF3, —CO2R′, —CON(R′)2, —COR′, —NR′C(O)R′, F, Cl, Br, I, or CF3S(O)r—; k is 1 or 2; m is 1, 2 or 3; n is 1 to 6; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began w

Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity

Vitronectin receptor antagonists having the formula: STR1 which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.